These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28099935)

  • 1. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
    Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
    Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D; Van Gorp J; Speel EJ; Ferdinande L
    Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
    Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
    Mod Pathol; 2024 Jun; 37(6):100494. PubMed ID: 38621503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical value of fluorescence
    Wang W; Li X; Liu P; Dong Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
    Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
    Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
    Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
    Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
    Przybyl J; Spans L; Ganjoo K; Bui N; Mohler D; Norton J; Poultsides G; Debiec-Rychter M; van de Rijn M
    PLoS One; 2022; 17(1):e0262272. PubMed ID: 34986184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
    Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A
    Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
    Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
    Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
    He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
    Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.